NCT03388242 is a clinical trial of No intervention in Mild Cognitive Impairment, sponsored by Sun Yat-sen University.

Who is sponsoring NCT03388242?

NCT03388242 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT03388242?

Interventions in NCT03388242: No intervention.

What condition does NCT03388242 study?

NCT03388242 studies Mild Cognitive Impairment.

Is NCT03388242 still recruiting?

NCT03388242 is currently withdrawn. Last updated 23 June 2023.

Last reviewed 2023-06-23 · How we verify

NCT03388242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protein and microRNA Markers for Early Detection of Alzheimer's Disease

Withdrawn Last updated 23 June 2023

What this trial tests

trial testing No intervention in Mild Cognitive Impairment. Withdrawn.

Timeline

7 December 2017

Primary endpoint
30 March 2020

30 March 2020

Quick facts

Lead sponsor	Sun Yat-sen University
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	7 December 2017
Primary completion	30 March 2020
Estimated completion	30 March 2020
Sites	2 locations across China

Drugs / interventions tested

No intervention

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Sun Yat-sen University

Who can join

Adults 30 to 80, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Blood will be harvested from three groups of people, normal control, patients with mild cognitive impairment (MCI) and patients with Alzheimer's disease (AD), 20 people per group. The blood samples will be used to determine the difference in the expression of microRNAs and proteins. Blood samples will be harvested again at 6-month interval from patients. The combination of the microRNAs and proteins that have different expression patterns between normal control and patients with MCI will be constructed in a kit to detect the difference. This kit will be used in another set of the three groups of people to determine its sensitivity and specificity in detecting patients with MCI.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

MicroRNAs as Potential Orchestrators of Alzheimer's Disease-Related Pathologies: Insights on Current Status and Future Possibilities.
Abuelezz NZ, Nasr FE, AbdulKader MA, Bassiouny AR, et al · · 2021 · cited 45× · PMID 34712129 · DOI 10.3389/fnagi.2021.743573
MicroRNA Networks in Cognition and Dementia.
Blount GS, Coursey L, Kocerha J. · · 2022 · cited 22× · PMID 35741010 · DOI 10.3390/cells11121882
Mechanism and Therapeutic Prospect of miRNAs in Neurodegenerative Diseases.
Ma YM, Zhao L. · · 2023 · cited 14× · PMID 38058356 · DOI 10.1155/2023/8537296

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03388242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 23 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03388242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing